Cargando…
Efficacy and safety of furosemide for prevention of intradialytic hypotension in haemodialysis patients: protocol for a multicentre randomised controlled trial
INTRODUCTION: Intradialytic hypotension (IDH) is a frequent and serious complication of maintaining haemodialysis (HD) patients and associated with subsequent cardiovascular events and higher mortality. Furosemide is commonly used in non-dialysis chronic kidney disease patients and can effectively m...
Autores principales: | Chen, Wenwen, Wang, Fang, Zhao, Yuliang, Zhang, Ling, Chen, Zhiwen, Dai, Mingjin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8258570/ https://www.ncbi.nlm.nih.gov/pubmed/34226226 http://dx.doi.org/10.1136/bmjopen-2020-048015 |
Ejemplares similares
-
Integrated strategies to prevent intradialytic hypotension: research protocol of the DialHypot study, a prospective randomised clinical trial in hypotension-prone haemodialysis patients
por: Peyronel, Francesco, et al.
Publicado: (2020) -
Association between haemoglobin concentration and intradialytic hypotension in patients undergoing maintenance haemodialysis: a retrospective cohort study
por: Hara, Takashi, et al.
Publicado: (2022) -
Impact of incremental versus conventional initiation of haemodialysis on residual kidney function: study protocol for a multicentre feasibility randomised controlled trial
por: Kaja Kamal, Raja Mohammed, et al.
Publicado: (2020) -
Hyperkalaemia prevalence, recurrence and treatment in patients on haemodialysis in China: protocol for a prospective multicentre cohort study (PRECEDE-K)
por: Ni, Zhaohui, et al.
Publicado: (2021) -
Evaluation of the effect of sodium zirconium cyclosilicate on arrhythmia-related cardiovascular outcomes in patients receiving chronic haemodialysis with hyperkalaemia: protocol for the multicentre, randomised, controlled DIALIZE-Outcomes study
por: Fishbane, Steven, et al.
Publicado: (2023)